This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
EC (2001a) Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products. Official journal N° L 311/67
EC (2001b) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to human medicinal products. Official journal N° L 311/1
EC (2001c) European Commission Directorate Health and Consumer Protection – Scientific Committee on Toxicity, Ecotoxicity and the Environment Opinion on: Draft CPMP Discussion Paper on Environmental Risk Assessment of Medicinal Products for Human Use [Non-Genetically Modified Organism (Non-GMO) Containing]. Report, Nr C2/JCD/csteeop/CPMPpaperRAssessHum Pharm12062001/D(01)
EEC (1980) Council Directive 80/68/EEC of 17 December 1979 on the protection of groundwater against pollution caused by certain dangerous substances. Official journal N° L 020
EEC (1981) Council Directive 81/851/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products. Official journal N° L 317
EEC (1993) Council Directive 93/39/EEC of 14 June 1993 amending Directives 65/65/EEC, 75/318/EEC and 75/319/EEC in respect of medicinal products. Official journal N° L 214
EEC (1995) Environmental Risk Assessment for Human Medicinal Products Containing or Consisting of GMOs. European Agency for the Evaluation of Medicinal Products, London, UK (Report no. EMEA/ CPMP/III/5507/94)
EMEA (1997) Environmental risk assessment for veterinary medicinal products other than gmo-containing and immunological products. European Agency for the Evaluation of Medicinal Products, London, UK (Report no. EMEA/CVMP/055/96)
EMEA (1998) Note for Guidance: Environmental risk assessment for veterinary medicinal products other than GMO-containing and immunological products. European Agen
EMEA (2001) Discussion paper on environmental risk assessment of non-genetically modified organisms (non gmo) containing medicinal products for human use. European Agency for the Evaluation of Medicinal Products, London, UK (Report no. CPMP/SWP/4447/00draft corr)
EMEA (2003) Note for guidance on environmental risk assessment for products of human use. European Agency for the Evaluation of Medicinal Products, London, UK (Report no. CPMP/SWP/4447/ 00draft)
EMEA (2005) Guideline on the environmental impact assessment of medicinal products for human use. European Agency for the Evaluation of Medicinal Products, London, UK (Report no. CPMP/SWP/ 4447/00 draft)
EMEA (2006) Guideline on the environmental impact assessment of medicinal products for human use. European Agency for the Evaluation of Medicinal Products, London, UK (Report no. CPMP/SWP/ 4447/00)
EMEA (2007) Environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 (Phase I) and GL38 (Phase II). European Agency for the Evaluation of Medicinal Products, London, UK (Report no. EMEA/CVMP/ERA/418282/2005-corr)
EU (2003) Technical Guidance Document in support of Commission Directive 93/67/EEC on Risk Assessment for new notified substances, Commission Regulation (EC) No 1488/94 on Risk Assessment for existing substances and Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market. EUR 20418 EN/1. European Chemicals Bureau, Ispra, Italy
FDA (1997) Retrospective review of ecotoxicity data submitted in environmental assessments for public display. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (Docket No. 96N-0057)
FDA (1998) U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), CMC 6 - Revision 1
VICH (2000) VICH Topic GL6 (Ecotoxicity Phase I) Step 7 Guideline on Environmental Impact Assessment (EIAs) for Veterinary Medicinal Products – Phase I. European Agency for the Evaluation of Medicinal Products, London, UK (Report no. CVMP/VICH/592/98)
VICH (2004) Guideline on environmental impact assessment for veterinary medicinal products Phase II. European Agency for the Evaluation of Medicinal Products, London, UK (Report no. CVMP/VICH/ 790/03-FINA)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Koschorreck, J., Hickmann, S. (2008). European Developments in the Environmental Risk Assessment of Pharmaceuticals. In: Kümmerer, K. (eds) Pharmaceuticals in the Environment. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-74664-5_20
Download citation
DOI: https://doi.org/10.1007/978-3-540-74664-5_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-74663-8
Online ISBN: 978-3-540-74664-5
eBook Packages: Earth and Environmental ScienceEarth and Environmental Science (R0)